P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon?
about
Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfallsReduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands.The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics.Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine.
P2860
P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon?
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon?
@en
type
label
P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon?
@en
prefLabel
P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon?
@en
P2860
P356
P1476
P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon?
@en
P2093
Adriana Dana Oprea
Wanda M Popescu
P2860
P304
P356
10.1155/2013/195456
P577
2013-02-19T00:00:00Z